NCT04673942 - A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

December 1, 2025

Study Completion Date

March 1, 2027

Conditions

Solid Tumor, AdultCancerNeoplasmsSarcomaSarcoma,Soft TissueChondrosarcoma

Interventions

BIOLOGICAL

AdAPT-001

Oncolytic virus administered by intratumoral injection

DRUG

Checkpoint Inhibitor, Immune

Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability

Trial Locations (6)

RECRUITING

Cleveland Clinic, Cleveland

ACTIVE_NOT_RECRUITING

Mary Crowley Cancer Research, Dallas

RECRUITING

MD Anderson Cancer Center, Houston

ACTIVE_NOT_RECRUITING

Providence Saint John's Health Center, Santa Monica

ACTIVE_NOT_RECRUITING

City of Hope, Duarte

ACTIVE_NOT_RECRUITING

California Cancer Associates for Research and Excellence, cCARE, San Marcos